Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: Hypertrophic cardiomyopathy, long-QT syndrome, and marfan syndrome: A statement for healthcare professionals from the councils on clinical cardiology, cardiovascular disease in the young, and basic science, American Heart Association

Circulation

Volumn 98, Issue 14, 1998, Pages 1460-1471

  Maron, Barry J ^a   Moller, James H ^a   Seidman, Christine E ^a   Vincent, G Michael ^a   Dietz, Harry C ^a   Moss, Arthur J ^a   Towbin, Jeffrey A ^a   Sondheimer, Henry M ^a   Pyeritz, Reed E ^a   McGee, Glenn ^a   Epstein, Andrew E ^a  

^a NONE

Author keywords

Cardiomyopathy, hypertrophic; Cardiovascular diseases; Diagnosis; Genetics; Long QT syndrome; Marian syndrome

Indexed keywords

CLINICAL FEATURE; DNA DETERMINATION; GENE LOCATION; GENE STRUCTURE; GENOTYPE; HERITABILITY; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MARFAN SYNDROME; NOTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032491158     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.14.1460     Document Type: Note

References (143)

1. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg H-P, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a β-cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006.
2. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donnis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372-1378.
3. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995;91:532-540.
4. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995;92:1336-1347.
5. Solomon SD, Jarcho JA, McKenna WJ, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990;86:993-999.
6. Kimura A, Harada H, Park J-E, Nishi H, Satoh M, Takabashi M, Hiroi S, Sasaoka T, Ohbuchi N, Nakamura T, Koyanagi T, Hwang T-H, Choo J-A, Chung K-S, Hasegawa A, Nagai R, Okazaki O, Nakamura H, Matsuzaki M, Sakamoto T, Toshima H, Koga Y, Imaizumi T, Sasazuki T. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16:379-382.
7. Watkins H, Rosenzweig A, Hwang D-S, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114.
8. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg H-P, Seidman JG, Seidman CE. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701-712.
9. Forissier J-F, Carrier L, Farza H, Bonne G, Bercovici J, Richard P, Hainque B, Townsend PJ, Yacoub MH, Faure S, Dabourg O, Millaire A, Hagege AA, Desnos M, Komajda M, Schwartz K. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation. 1996;94:3069-3073.
10. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058-1064.
11. Moolman J, Corfield VA, Posen B, Ngumbela K, Seidman CE, Brink PA, Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997;29:549-555.
12. Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in α-tropomyosin that causes hypertrophic cardiomyopathy. Circulation. 1995;91:2302-2305.
13. Coviello DA, Maron BJ, Spirito P, Watkins H, Vosberg H-P, Thierfelder L, Schoen FJ, Seidman JG, Seidman CE. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol. 1997;29:635-640.
14. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Beckmann J, Weissenbach J, Vosberg H-P, Fiszman M, Komajda M, Schwartz K. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:438-440.
15. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, Seidman JG, Seidman CE. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:434-437.
16. Rottbauer W, Gautel M, Zehelein J, Labeit S, Franz WM, Fischer C, Vollrath B, Mall G, Dietz R, Kubler W, Katus HA. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy: characterization of cardiac transcript and protein. J Clin Invest. 1997;100:475-482.
17. Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, Hainque B, Cruaud C, Gary F, Labeit S, Bonhour JB, Dubourg O, Desnos M, Hagege AA, Trent RJ, Komajda M, Fiszman M, Schwartz K. Organization and sequence of human cardiac myosin binding protein C gene (MyBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res. 1997;80:427-434.
18. Marian AJ, Mares A Jr, Kelly DP, Yu Q-T, Abchee AB, Hill R, Roberts R. Sudden cardiac death in hypertrophic cardiomyopathy: variability in phenotypic expression of β-myosin heavy chain mutations. Eur Heart J. 1995;16:368-376.
19. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, Mares A Jr, Towbin JA, Spirito P, Roberts R, Seidman JG, Seidman CE. Prognostic implication of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280-285.
20. Rosenzweig A, Watkins H, Hwang D-S, Miri M, McKenna W, Traill TA, Seidman JG, Seidman CE. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753-1760.
21. Greve G, Bachinski L, Friedman DL, Czernuszewicz G, Anan R, Towbin J, Seidman CE, Roberts R. Isolation of a de novo mutant myocardial βMHC protein in a pedigree with hypertrophic cardiomyopathy. Hum Mol Genet. 1994;3:2073-2075.
22. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, Sellers JR, Fananapazir L, Epstein ND. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996; 13:63-69.
23. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Millaire A, Carrier L, Bonne G, Tesson F, Richard P, Bouhour J-B, Schwartz K, Komajda M. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation. 1997;96:214-219.
24. MacRae CA, Ghaisas N, Kass S, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest. 1995;96:1216-1220.
25. Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneux M, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome Iq3. Nat Genet. 1993;3:333-337.
26. Thierfelder LC, MacRae C, Watkins H, et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A. 1993;90:6270-6274.
27. Carrier L, Hengstenberg C, Beckmann JS, et al. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet. 1993;4:311-313.
28. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG, Seidman CE. Mutations in the gene for cardiac myosin binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248-1257.
29. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992;327:846-852.
30. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683-685.
31. Grace AA, Chien KR. Congenital long QT syndromes: toward molecular dissection of arrhythmia substrates. Circulation. 1995;92: 2786-2789.
32. Keating MT. Genetic approaches to cardiovascular disease: supravalvular aortic stenosis, Williams syndrome, and long-QT syndrome. Circulation. 1995;92:142-147.
33. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation. 1996;94:1996-2012.
34. Towbin JA. New revelations about the long-QT syndrome. N Engl J Med. 1995;333:384-385.
35. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991;252:704-706.
36. Benhorin J, Kalman YM, Medina A, Towbin J, Rave-Harel N, Dyer TD, Blangero J, MacCluer JW, Karem BS. Evidence of genetic heterogeneity in the long QT syndrome. Science. 1993;260:1960-1962.
37. Jiang C, Atkinson D, Towbin JA, Splawski I, Lehmann MH, Li H, Timothy K, Taggart RT, Schwartz PJ, Vincent GM, Moss AJ, Keating MT. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet. 1994;8:141-147.
38. Towbin JA, Li H, Taggart RT, Lehmann MH, Schwartz PJ, Satler CA, Ayyagari R, Robinson JL, Moss A, Hejtmancik F. Evidence of genetic heterogeneity in Romano-Ward long QT syndrome: analysis of 23 families. Circulation. 1994;90:2635-2644.
39. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12:17-23.
40. Tanaka T, Nagai R, Tomoike H, Takata S, Uyano K, Yabuta K, Haneda N, Nakano O, Shibata A, Sawayama T, Kasai H, Yazaki Y, Nakamura Y. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation. 1997;95:565-567.
41. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15:186-189.
42. Keating MT. Genetic approaches to cardiovascular disease: supravalvular aortic stenosis, Williams syndrome, and long-QT syndrome. Circulation. 1995;92:142-147.
43. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.
44. Kr potassium channel. Cell. 1995;81:299-307.
45. + channel-linked long-QT syndrome. Circ Res. 1996;78:916-924.
46. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92: 3381-3386.
47. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384:80-83.
48. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature. 1996;384:78-80.
49. + channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A. 1996;93:2208-2212.
50. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
51. Splawski I, Timothy KW, Vincent GM, Atkinson DL, Keating MT. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med. 1997;336:1562-1567.
52. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet. 1997;17:267-268.
53. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin S, Stellen G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mulation in the fibrillin gene. Nature. 1991;352: 337-339.
54. Magenis RE, Maslen CL, Smith L, Allen L, Sakai LY. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics. 1991;11:346-351.
55. Tsipouras P, Del Mastro R, Sarfarazi M, Lee B, Vitale E, Child AH, Godfrey M, Devereux RB, Hewetl D, Steinmann B, Viljoen D, Sykes BC, Kilpatrick M, Ramirez F, and the Internalional Marfan Syndrome Collaborative Study. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. N Engl J Med. 1992;326:905-909.
56. Dietz HC, Pyeritz RE, Hall BD, et al. The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics. 1991;9:355-361.
57. Dietz H, Francke U, Furthmayr H, Francomano C, De Paepe A, Devereux R, Ramirez F, Pyeritz R. The question of heterogeneity in Marfan syndrome. Nat Genet. 1995;9:228-231.
58. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet. 1995;4:1799-1809.
59. Aoyama T, Tynan K, Dietz HC, Francke U, Furthmayr H. Missense mutations impair intracellular processing of fibrillin and microfibril assembly in Marfan syndrome. Hum Mol Genet. 1993;2:2135-2140.
60. Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, Ramirez F, Pyeritz RE, Dietz HC. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet. 1995;57:8-21.
61. Godfrey M, Vandemark N, Wang M, Velinov M, Wargowski D, Tsipouras P, Han J, Becker J, Robertson W, Droste S, Rao VH. Prenatal diagnosis and a donor splice site mutation in fibrillin in a family with Marfan syndrome. Am J Hum Genet. 1993;53:472-480.
62. Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat Genet. 1994;6:64-69.
63. Pereira L, D'Alessio M, Ramirez F, Lynch JR, Sykes B, Pangilinan T, Bonadio J. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet. 1993; 2:961-968.
64. Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T. A mutation in FBN1 disrupts profibriilin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest. 1995;95: 2373-2378.
65. Dietz HC, McIntosh I, Sakai LY, Corson GM, Chalberg SC, Pyeritz RE, Francomano CA. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics. 1993;17:468-475.
66. Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med. 1990;323:935-939.
67. Dietz HC. Molecular etiology, pathogenesis and diagnosis of the Marfan syndrome. Prog Ped Cardiol. 1996;5:159-166.
68. Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science. 1996;274:621-624.
69. Rothenberg K, Fuller B, Rothstein M, Duster T, Ellis-Kahn MJ, Cunningham R, Fine B, Hudson K, King M-C, Murphy P, Swergold G, Collins F. Genetic information and the workplace: legislative approaches and policy changes. Science. 1997;275:1755-1757.
70. American Society of Human Genetics and American College of Medical Genetics Report. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents: American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet. 1995;57: 1233-1241.
71. Maron BJ, Mitchell JH. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol. 1994;24:845-899.
72. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-18.
73. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127-133.
74. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985; 28:1-83.
75. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.
76. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-789, 844-852.
77. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92: 1680-1692.
78. Louie EK, Edwards LC III. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994;36:275-308.
79. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320:749-755.
80. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995;26:1529-1536.
81. Maron BJ, Poliac LC, Casey SA, Lange SK, Aeppli D. Clinical significance and consequences of hypertrophic cardiomyopathy assessed in an unselected patient population: evidence for the relatively benign nature of the true disease state in adulthood. Circulation. 1996;94(suppl I):I-84. Abstract.
82. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol. 1993;72:939-943.
83. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26: 1699-1708.
84. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy. Circulation. 1995;91:1596-1601.
85. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37:59-88.
86. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651-1660.
87. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 1991;84:1188-1197.
88. Klues HG, Roberts WC, Maron BJ. Morphologic determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87: 1570-1579.
89. Ciró E, Nichols PF III, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: two-dimensional echocardiographic analysis. Circulation. 1983;67: 1227-1233.
90. Shirani J, Pick R, Silver MA, Roberts WC, Maron BJ. Importance of collagen matrix in young patients with hypertrophic cardiomyopathy and sudden death. J Am Coll Cardiol. 1994;23(suppl 2):110A. Abstract.
91. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557.
92. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y, Kawai C. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75:1130-1139.
93. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993;72:970-972.
94. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild D. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study: Coronary Artery Risk Development in (young) Adults. Circulation. 1995;92:785-789.
95. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418-428.
96. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983;2:437-444.
97. Roberts CS, Roberts WC. Morphologic features. In: Zipes DP, Rowlands DJ, eds. Progress in Cardiology 2/2. Philadelphia, Pa: Lea & Febiger; 1989:3-22.
98. Olsen EG. Anatomic and light microscopic characterization of hypertrophic obstructive and non-obstructive cardiomyopathy. Eur Heart J. 1983;4(suppl F):1-8.
99. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242-1244.
100. Maron BJ, Nichols PF III, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy. Assessment by M-mode and two-dimensional echocardiography. Am J Cardiol. 1984;53: 1087-1094.
101. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol. 1989;13:36-45.
102. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly: distinctions from the young based on cardiac shape. Circulation. 1989;79:580-589.
103. Chikamori T, Doi YL, Yonezawa Y, Dickie S, Ozawa T, McKenna WJ. Comparison of clinical features in patients ≥60 years of age to those ≤40 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 1990;66:875-877.
104. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614.
105. Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, Seidman CE, Lee RT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the β-myosin heavy chain gene. J Am Coll Cardiol. 1993;22:498-505.
106. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, Watkins H, Reggiani C. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res. 1998;82:106-115.
107. Lechin M, Quiñones MA, Omran A, Hill R, Yu Q-T, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation. 1995;92: 1808-1812.
108. Marian AJ, Yu Q-T, Workman R, Greve G, Roberts R. Angiotensin converting enzyme in polymorphism, hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342:1085-1086.
109. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in età pediatrica. Clin Pediatr. 1963;45:656-683.
110. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc. 1964;54:103-106.
111. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, Robinson JL, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
112. Weintraub RG, Gow RM, Wilkinson JL. The congenital long QT syndrome in childhood. J Am Coll Cardiol. 1990;16:674-680.
113. Zareba W, Moss AJ, le Cessie S, Locati EH, Robinson JL, Hall WJ, Andrews ML. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol. 1995;26:1685-1691.
114. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88:782-784.
115. Garson A Jr. How to measure the QT interval: what is normal? Am J Cardiol. 1993;72:14B-16B.
116. Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP, Tansuphaswadikul S, Campbell RW. Importance of lead selection in QT interval measurement. Am J Cardiol. 1988;61:83-87.
117. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation. 1994;89:1681-1689.
118. Lehmann MH, Suzuki F, Fromm BS, Frankovich D, Elko P, Steinman RT, Fresard J, Baga JJ, Taggart RT. T wave "humps" as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol. 1994;24:746-754.
119. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995; 92:2929-2934.
120. c) interval during acute myocardial infarction. J Am Coll Cardiol. 1985;5: 699-702.
121. Lehmann MH, Timothy KW, Frankovich D, Fromm BS, Keating M, Locati EH, Taggart RT, Towbin JA, Moss AJ, Schwartz PJ, Vincent GM. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol. 1997;29:93-99.
122. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol. 1991;68:498-503.
123. Schott J-J, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour J-B, Donnelly P, Vergnaud G, Bachner L, Moisan J-P, Le Marec H, Pascal O. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet. 1995;57:1114-1122.
124. Napolitano C, Priori SG, Schwartz PJ, Matteo PS, Timothy K, Paganini V, Cantu F, Bloisi R, de Fusco M, Spazzolini C, Casari G. Identification of a mutational hot spot in HERG-related long QT syndrome (LQT2): phenotypic implications. Circulation. 1997;96(suppl I):I-212. Abstract.
125. Marfan AB. Un cas de formation congenitale des quatre: membres plus prononcé aux extrémités charactériseé par l'allongement des os avec un certain degré d'amincissement. Bull Mém Soc Méd Hôp Paris. 1896;13: 220-226.
126. Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. The prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome. J Am Coll Cordial. 1993;22:1470-1476.
127. Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol. 1989;63:317-321.
128. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue: a phenotypic continuum. JAMA. 1989;262:523-528.
129. Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med. 1979;300:772-777.
130. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157-160.
131. Marsalese DL, Moodie DS, Vacante M, Lytle BW, Gill CC, Sterba R, Cosgrove DM, Passalacqua M, Goormastic M, Kovacs A. Marfan's syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol. 1989;14:422-428.
132. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330:1335-1341.
133. Gott VL, Laschinger JC, Cameron DE, Dietz HC, Greene PS, Gillinov AM, Pyeritz RE, Alejo DE, Fleischer KJ, Anhalt GJ, Stone CD, McKusick VA. The Marfan syndrome and the cardiovascular surgeon. Eur J Cardiorthorac Surg. 1996;10:149-158.
134. Beighton P, de Paepe A, Danks D, Finidori G, Gedde-Dahl T, Goodman R, Hall JG, Hollister DW, Horton W, McKusick VA, Opitz JM, Pope FM, Pyeritz RE, Rimoin DL, Sillence D, Spranger JW, Thompson E, Tsipouras P, Viijoen D, Winship I, Young I. International nosology of heritable disorders of connective tissue, Berlin, 1986. Am J Med Genet. 1988;29:581-594.
135. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62:417-426.
136. Pereira L, Levran O, Ramirez F, Lynch JR, Sykes B, Pyeritz RE, Dietz HC. A molecular approach to the stratification of cardiovascular risk in families with Marfan's syndrome. N Engl J Med. 1994;331:148-153.
137. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 3rd ed. New York, NY: Oxford University Press; 1989.
138. Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, Grana G, Daly MB, Schneider K, Kahn MJ. Genetic testing for susceptibility to adult-onset cancer: the process and content of informed consent. JAMA. 1997;277:1467-1474.
139. Olopade OI. Genetics in clinical cancer care: the future is now. N Engl J Med. 1996;335:1455-1456. Editorial.
140. Burke W, Daly M, Garber J, Botkin J, Ellis Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2: Cancer Genetics Studies Consortium. JAMA. 1997;277:997-1003.
141. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
142. Healy B. BRCA genes: bookmaking, fortunetelling, and medical care. N Engl J Med. 1997;336:1448-1449.
143. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324:295-301.